论文分享丨CCL20助力自身免疫性皮肤疾病研究

2023年10月19日,深圳中山大学Rufan Huang, Bo Jia等人在Journal of Extracellular VesiclesIF=16在线发表题为“Plant exosomes fused with engineered mesenchymal stem cell-derived nanovesicles for synergistic therapy of autoimmune skin disorders”的论文,此论文使用了联科生物Mouse CCL20/MIP-3α ELISA Kit 货号:EK2211)检测试剂盒(Fig.1)。

图像310.PNG

Fig.1ELISA assay to detect the CCL20 in the skin tissues of mice in each group .

该研究首先将装载了CX5461的葡萄柚来源的外泌体样纳米囊泡(Grapefruit‐derived exosome‐like nanovesicles,GEVs)与基因工程牙龈间充质干细胞(Gingiva‐derived mesenchymal stem cells,GMSCs)来源的CCR6‐NVs进行融合,从而获得多功能融合囊泡(FV @ CX5461),原理图见Fig.2。研究结果表明,FV @ CX5461不仅保持GEV、CX5461和GMSC三者的生物活性,而且通过CCR6对FVs的趋化作用,使富含趋化因子CCL20的炎症组织归巢。在银屑病和特应性皮炎疾病模型中,FV @ CX5461可减少炎症因子的分泌,减少Th17细胞活化,诱导Treg细胞浸润,实现重塑失衡的免疫微环境,最终实现治疗效果。FV @ CX5461可能为自身免疫性疾病的靶向免疫治疗提供新的前景。

Fig.2 Schematic illustration showing the preparation process of FV@CX5461 and their therapeutic effects for autoimmune skin disorders.

联科生物产品助力生命科学研究


参考文献:

Zhang M, Qin X, Gao Y, et al. Transcutaneous Immunotherapy for RNAi: A Cascade-Responsive Decomposable Nanocomplex Based on Polyphenol-Mediated Framework Nucleic Acid in Psoriasis. Adv Sci (Weinh). 2023 Nov;10(33):e2303706. doi: 10.1002/advs.202303706. Epub 2023 Oct 5. PMID: 37797168; PMCID: PMC10667853.

原文链接:

https://onlinelibrary.wiley.com/doi/full/10.1002/jev2.12361